Hasan Qutob, MD
Endocrinology, Diabetes & Metabolism · Jackson, MINPI 1285793521
Payments from drug & device makers
Across 242 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$957
- Abbott$499
- Novo Nordisk$443
- Corcept Therapeutics$361
- Tandem Diabetes Care, Inc.$272
- Medtronic$239
- plus $2K from 29 others
What the payments were for
- Consulting fees$85016%
- Food & beverage$4,24881%
- Education$912%
- Other$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 6 | $957 |
| Abbott | 16 | $499 |
| Novo Nordisk | 33 | $443 |
| Corcept Therapeutics | 26 | $361 |
| Tandem Diabetes Care, Inc. | 11 | $272 |
| Medtronic(2 entities) | 9 | $239 |
| Amgen | 15 | $239 |
| Lilly USA, LLC | 13 | $218 |
| Xeris Pharmaceuticals, Inc. | 11 | $217 |
| Boehringer Ingelheim | 12 | $209 |
| AstraZeneca(2 entities) | 11 | $180 |
| Merck | 9 | $161 |
| Dexcom, Inc. | 8 | $141 |
| Sanofi-aventis U.S. LLC | 4 | $124 |
| Daiichi Sankyo Inc. | 1 | $122 |
| Novartis | 6 | $117 |
| Johnson & Johnson | 19 | $108 |
| Ascendis Pharma Endocrinology Inc | 6 | $103 |
| Madrigal Pharmaceuticals | 3 | $87 |
| Radius Health, Inc. | 3 | $62 |
| Alvogen Inc | 3 | $50 |
| United Therapeutics Corporation | 2 | $44 |
| Neurocrine Biosciences, Inc. | 1 | $37 |
| Bayer | 2 | $35 |
| BETA Bionics, Inc. | 2 | $28 |
| Amphastar Pharmaceuticals, Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $22 |
| Rhythm Pharmaceuticals, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Valeritas, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$850
- INJECTAFER$122
How this compares
$5,238 in reported general payments places this provider in the 65th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 727 | $1,225,167 |
| JardianceEmpagliflozin | 992 | $1,080,745 |
| OzempicSemaglutide | 508 | $830,076 |
| FarxigaDapagliflozin Propanediol | 555 | $540,064 |
| TrulicityDulaglutide | 236 | $344,284 |
| JanuviaSitagliptin Phosphate | 264 | $320,403 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 178 | $193,610 |
| InvokanaCanagliflozin | 112 | $133,989 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 715 | $126,991 |
| Humulin R U-500Insulin Regular, Human | 53 | $101,769 |
| Tresiba Flextouch U-100Insulin Degludec | 156 | $99,710 |
| Novolog FlexpenInsulin Aspart | 375 | $85,010 |
| Tolvaptan | 20 | $76,010 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $74,350 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $66,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $218 | $1,638,0691,050 claims |
| Boehringer IngelheimJardiance | $209 | $1,080,745992 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $443 | $931,859686 claims |
| AstraZenecaFarxiga | $180 | $540,064555 claims |
| MerckJanuvia, Janumet Xr | $161 | $339,021276 claims |
| Johnson & JohnsonInvokana | $108 | $133,989112 claims |
| Alvogen IncTeriparatide | $50 | $52,31023 claims |
| Sanofi-aventis U.S. LLCLantus | $124 | $35,563180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Jackson
- Wassim NoureddineJackson$47K
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.